Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial
Prelude Therapeutics (PRLD) and Eli Lilly (LLY) will collaborate to evaluate PRT13722 in a breast cancer trial. The Phase 1 study will test PRT13722 with Lilly's Verzenio and Inluriyo in HR+/HER2- breast cancer patients. Prelude's IND application was cleared by the FDA, with enrollment expected in Q4 2026. Preclinical data showed PRT13722's potential as a monotherapy and in combination therapies. PRLD's stock closed at $3.74 on Monday, up 6.42% in pre-market trading.
How this was made
The 30-second read
Why it matters
The IND clearance and partnership provide a clear path to clinical data, which could de‑risk the company and attract investors.
Market read
First disclosure of a new oncology trial partnership, likely to move Prelude's stock and modestly affect Lilly.
What to watch
Potential competition from other KAT6A/B inhibitors and the need for further funding.
Background
Prelude Therapeutics is a clinical‑stage biotech developing novel epigenetic therapies; Eli Lilly is a large pharma with established breast‑cancer drugs.
Ticker impact
Prelude Therapeutics announced a new clinical trial collaboration with Eli Lilly and received FDA IND clearance for PRT13722.
likely upside as investors price in potential future approvals
First report of IND clearance and partnership with a major pharma partner.
Eli Lilly will supply Verzenio and Inluriyo for Prelude's Phase 1 study of PRT13722.
likely limited impact, modest upside if trial shows promise
Lilly is a party to the deal but the news centers on Prelude's trial progress.
Market effects
Adds to momentum in the oncology biotech sector as new KAT6A degrader enters trials.
US biotech market may see modest uplift from the partnership announcement.
Limited to investors focused on US biotech and oncology pipelines.
Counterpoint
The trial may face delays or fail to differentiate, limiting upside for Prelude.
Key entities
- companyPrelude Therapeutics
Developer of PRT13722, a KAT6A selective degrader.
- companyEli Lilly and Company
Supplier of Verzenio and Inluriyo for the combination trial.
